Table 2. The association between IFN-γ and sustained virologic response in HCV patients.
| IFN-γ (pg/ml) | SVR | >Non-SVR | X2 p-value | Multivariate p-value | p-value |
|---|---|---|---|---|---|
| (n = 73) | (n = 19) | OR (95% C.I) | |||
| IFN-γ 4wk | |||||
| <180 | 64(86.5%) | 10(13.5%) | 6.0 × 10−4 | 6.79 (1.91~24.09) | 3.0 × 10−3 |
| ≧180 | 9(50.0%) | 9(50.0%) | |||
| IFN-γ 12wk | |||||
| <120 | 53(89.8%) | 6(10.2%) | 9.0 × 10−4 | 11.55 (3.05~43.77) | 3.2 × 10−4 |
| ≧120 | 20(60.6%) | 13(39.4%) | |||
| IFN-γ EOT | |||||
| <40 | 52(89.7%) | 6(10.3%) | 1.4 × 10−3 | 4.93 (1.52~15.93) | 7.7 × 10−3 |
| ≧40 | 21(61.8%) | 13(38.2%) | |||
p.s. Adjusted for viral load and GPT. EOT: end of treatment.